Establishing the feasibility of measuring performance in use of addiction pharmacotherapy

Journal of Substance Abuse Treatment

Volumn 45, Issue 1, 2013, Pages 11-18

  Thomas, Cindy Parks ^a   Garnick, Deborah W ^a   Horgan, Constance M ^a   Miller, Kay ^c   Harris, Alex H S ^b   Rosen, Melissa M ^a  

^a BRANDEIS UNIVERSITY   (United States)

^b CENTER FOR HEALTH CARE EVALUATION   (United States)

^c IBM WATSON HEALTH   (United States)

Author keywords

Addiction medication; Medicaid; Performance measurement; Pharmacotherapy; Veterans health

Indexed keywords

ACAMPROSATE; BUPRENORPHINE; DISULFIRAM; METHADONE; NALTREXONE;

ADULT; ALCOHOL ABUSE; ALCOHOLISM; ARTICLE; COUNSELING; DRUG DEPENDENCE TREATMENT; EVIDENCE BASED PRACTICE; FEASIBILITY STUDY; FEMALE; FOOD AND DRUG ADMINISTRATION; HEALTHCARE COMMON PROCEDURE CODING SYSTEM; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAID; METHADONE TREATMENT; OPIATE ADDICTION; OUTPATIENT CARE; PERFORMANCE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; STANDARDIZATION;

ADOLESCENT; ADULT; ALCOHOLISM; DATABASES, FACTUAL; DRUG APPROVAL; EVIDENCE-BASED PRACTICE; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; OPIOID-RELATED DISORDERS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PILOT PROJECTS; SUBSTANCE-RELATED DISORDERS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; YOUNG ADULT;

EID: 84876995466     PISSN: 07405472     EISSN: 18736483     Source Type: Journal    
DOI: 10.1016/j.jsat.2013.01.004     Document Type: Article

References (74)

1. 111th Congress The Patient Protection and Affordable Care Act. Publie Law 2010, 111-148.
2. Academy Health Glossary of terms commonly used in health care 2004.
3. Albright J., Ciaverelli R., et al. Psychiatrist characteristics that influence use of buprenorphine medication-assisted treatment. Journal of Addiction Medicinee 2010, [pub ahead of print].
4. Amass L., Ling W., et al. Bringing buprenorphine-naloxone detoxification to community treatment providers: The NIDA Clinical Trials Network field experience. The American Journal on Addictions 2004, 13(Suppl 1):S42-S66.
5. American Medical Association (AMA) Substance use disorders physician performance measurement set. American Medical Association (AMA) July 2008, American Psychiatric Association (APA), Physician Consortium for Performance Improvement® (PCPI), National Committee for Quality Assurance (NCQA), Chicago, IL.
6. Arfken C.L., Johanson C., et al. Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: National surveys of physicians. Journal of Substance Abuse Treatment 2010, 39:96-104.
7. Barnett P.G., Zaric G.S., et al. The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States. Addiction 2001, 96:1267-1278.
8. Baros A.M., Latham P.K., et al. What role does measuring medication compliance play in evaluating the efficacy of naltrexone?. Alcoholism, Clinical and Experimental Research 2007, 31:596-603.
9. Baser O., Chalk M., et al. Cost and utilization outcomes of opioid-dependence treatments. The American Journal of Managed Care 2011, 17(Suppl 8):S235-S248.
10. Baser O., Chalk M., et al. Alcohol dependence treatments: Comprehensive healthcare costs, utilization outcomes, and pharmacotherapy persistence. The American Journal of Managed Care 2011, 17(Suppl 8):S222-S234.
11. Brook R.H., McGlynn E.A., et al. Defining and measuring quality of care: A perspective from US researchers. International Journal for Quality in Health Care 2000, 12:281-295.
12. Bryson W.C., McConnell J., et al. Extended-release naltrexone for alcohol dependence: Persistence and healthcare costs and utilization. The American Journal of Managed Care 2011, 17(Suppl 8):S222-S234.
13. Center for Substance Abuse Treatment Treatment Improvement Protocol (TIP) Series 28: Naltrexone And Alcoholism Treatment 1998, Substance Abuse and Mental Health Services Administration (SAMHSA), Rockville, MD.
14. Center for Substance Abuse Treatment Treatment Improvement Protocol (TIP) Series 40: Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 2004, Substance Abuse and Mental Health Services Administration (SAMHSA) Center for Substance Abuse Treatment (CSAT).
15. Center for Substance Abuse Treatment Treatment Improvement Protocol (TIP) Series 49: Incorporating Alcohol Pharmacotherapies Into Medical Practice. Treatment Improvement Protocol (TIP) Series 49 2009, Substance Abuse and Mental Health Services Administration (SAMHSA), Rockville, MD.
16. Centers for Disease Control and Prevention International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Retrieved November 9, 2012, from. http://www.cdc.gov/nchs/icd/icd10cm.htm#10update.
17. Clark R.E., Samnaliev M., et al. The evidence doesn't justify steps by state Medicaid programs to restrict opioid addiction treatment with buprenorphine. Health Affairs (Project Hope) 2011, 30:1425-1433.
18. Deas D. Evidence-based treatments for alcohol use disorders in adolescents. Pediatrics 2008, 121(Supplement 4):S348.
19. Fernandes-Taylor S., Harris A.H. Comparing alternative specifications of quality measures: Access to pharmacotherapy for alcohol use disorders. Journal of Substance Abuse Treatment 2012, 42:102-107.
20. Fiellin D.A., O'Connor P.G., et al. Methadone maintenance in primary care: A randomized controlled trial. JAMA: The Journal of the American Medical Association 2001, 286:1724-1731.
21. Galvin R.S., McGlynn E.A. Using performance measurement to drive improvement: A road map for change. Medical Care 2003, 41(1 Supplement):148-160.
22. Garnick D., Lee M., et al. Lessons from five states: Public sector use of the Washington Circle performance measures. Journal of Substance Abuse Treatment 2011, 40:241-254.
23. Garnick D.W., Lee M.T., et al. Establishing the feasibility of performance measures for alcohol and other drugs. Journal of Substance Abuse Treatment 2002, 23:375-385.
24. Garnick D.W., Lee M.T., et al. Adapting Washington Circle performance measures for public sector substance abuse treatment systems. Journal of Substance Abuse Treatment 2009, 36:265-277.
25. Gelber S.A. State Financing For Medication-Assisted Treatment: Results And Observation From A 50-State NCSL/AVISA Survey (March 2008) 2008, Medication Assisted Treatment for Opiate Addiction, National Council of State Legislators.
26. Gurewich D., Sirkin J.T., et al. On-site provision of substance abuse treatment services at community health centers. Journal of Substance Abuse Treatment 2011.
27. Harris A.H., Kivlahan D.R., et al. Pharmacotherapy of alcohol use disorders in the Veterans Health Administration. Psychiatric Services (Washington, D.C.) 2010, 61:392-398.
28. Harris A.H.S., Humphreys K., et al. Measuring the quality of substance use disorder treatment: Evaluating the validity of the Department of Veterans Affairs continuity of care performance measure. Journal of Substance Abuse Treatment 2009, 36:294-305.
29. Harris A.H.S., Reeder R.N., et al. Validation of the treatment identification strategy of the HEDIS addiction quality measures: Concordance with medical record review. BMC Health Services Research 2011, 11:73.
30. Heinala P., Alho H., et al. Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: A factorial double-blind, placebo-controlled trial. Journal of Clinical Psychopharmacology 2001, 21:287-292.
31. Horgan C.M., Garnick D. The quality of care for adults with m ental and addictive disorders: Issues in performance measurement. Background paper for the Institute of Medicine 2005, Institute for Behavioral Health, Heller School for Social Policy and Management, Brandeis University, Waltham.
32. Horgan C.M., Reif S., et al. Availability of addiction medications in private health plans. Journal of Substance Abuse Treatment 2008, 34:147-156.
33. Institute of Medicine Performance Measurement: Accelerating Improvement (Pathways to Quality Health Care Series) 2006, The National Academies Press, Washington DC.
34. Jan S., Gill P., et al. Utilization patterns of extended-release naltrexone for alcohol dependence. The American Journal of Managed Care 2011, 17(Suppl 8):S210-S212.
35. Jencks S., Cuerdon T., et al. Quality of medical care delivered to Medicare beneficiaries: A profile at state and national levels. JAMA: The Journal of the American Medical Association 2000, 284:1670.
36. Kaiser Commission on Medicaid and the Uninsured, W., D.C. Performance measurement under health reform: Proposed measures for eligibility and enrollment systems and key issues and trade-offs to consider (Issue Brief) 2011, Washington, D.C.
37. Kranzler H.R., Gage A. Acamprosate efficacy in alcohol-dependent patients: Summary of results from three pivotal trials. The American Journal on Addictions 2008, 17:70-76.
38. Kranzler H.R., Rosenthal R.N. Dual diagnosis: Alcoholism and co-morbid psychiatric disorders. The American Journal on Addictions 2003, 12(Suppl. 1):S26-S40.
39. Kresina T.F., Litwin A., et al. United States Government oversight and regulation of medication assisted treatment for the treatment of opioid dependence. Journal of Deug Policy Analysis 2009, 2:1-23.
40. Krumholz H., Normand S., et al. Measuring performance for treating heart attacks and heart failure: The case for outcomes measurement. Health Affairs 2007, 26:75.
41. Ling W., Jacobs P., et al. From research to the real world: Buprenorphine in the decade of the Clinical Trials Network. Journal of Substance Abuse Treatment 2010, 38(Suppl 1):S53-S60.
42. Malinoff H., Barkin R., et al. Sublingual buprenorphine is effective in the treatment of chronic pain syndrome. American Journal of Therapeutics 2005, 12:379.
43. Manfredonia J. Prescribing methadone for pain management in end-of-life care. JAOA: Journal of the American Osteopathic Association 2005, 105(3 supplement):18S.
44. Mant J. Process versus outcome indicators in the assessment of quality of health care. International Journal for Quality in Health Care 2001, 13:475-480.
45. Mark T.L., Kassed C.A., et al. Alcohol and opioid dependence medications: Prescription trends, overall and by physician specialty. Drug and Alcohol Dependence 2009, 99:345-349.
46. Mark T.L., Montejano L.B., et al. Comparison of healthcare utilization among patients treated with alcoholism medications. The American Journal of Managed Care 2010, 16:879-888.
47. McCaul M.E., Monti P.M. Research priorities for alcoholism treatment. Recent Developments in Alcoholism 2003, 16:405-414.
48. National Committee for Quality Assurance The State of Health Care Quality 2011 2011, Washington, DC.
49. National Committee for Quality Assurance Hedis Archives Retrieved November 15, 2012, from. http://www.ncqa.org/HEDISQualityMeasurement/HEDISMeasures/HEDISArchives.aspx.
50. National Institute on Alcohol Abuse and Alcoholism (NIAAA) Helping Patients Who Drink Too Much: A Clinician's Guide, 2006 Edition 2006, N. I. o. A. A. a. Alcoholism, National Institutes of Health.
51. Evidence-based treatment practices for substance use disorders 2005, National Quality Forum (NQF), Washington DC.
52. National Quality Forum (NQF) National voluntary consensus standards for the treatment of substance use conditions: Evidence-based treatment practices 2007, Washington DC.
53. NQF Endorsed Standards: NQF#0004, Initiation and Engagement of Alcohol and Other Drug Dependence Treatment National Quality Forum (NQF), Retrieved February 6, 2012, from. http://www.qualityforum.org/MeasureDetails.aspx?actid=0&SubmissionId=1245#k=engagement&e=1&st=&sd=&s=n&so=a&p=1&mt=&cs=&ss.
54. Oliva E., Harris A.H.S., et al. Receipt of opioid agonist therapy in the Veteran Health Administration: Facility and patient factors. Drug and Alcohol Dependence 2012, 122:241-246.
55. Oliva, E. M., A. J. Gordon, et al. ((in press)). "Trends in opioid agonist therapy in the Veterans Health Administration: Is supply keeping up with demand?." The American Journal of Drug and Alcohol Abuse.
56. Oliva E.M., Maisel N.C., et al. Barriers to use of pharmacotherapy for addiction disorders and how to overcome them. Current Psychiatry Reports 2011, 13:374-381.
57. Pettinati H.M., Volpicelli J.R., et al. Improving naltrexone response: An intervention for medical practitioners to enhance medication compliance in alcohol dependent patients. Journal of Addictive Diseases 2000, 19:71-83.
58. Pincus H.A., Spaeth-Rublee B., et al. Analysis & commentary: The case for measuring quality in mental health and substance abuse care. Health Aff (Millwood) 2011, 30:730-736.
59. Post E.P., Metzger M., et al. Integrating mental health into primary care within the Veterans Health Administration. Families, Systems & Health 2010, 28:83.
60. Purbey S., Mukherjee K., et al. Performance measurement system for healthcare processes. International Journal of Productivity and Performance Management 2007, 56:241-251.
61. Rieckmann T., Kovas A.E., et al. Adoption of medications in substance abuse treatment: Priorities and strategies of single state authorities. Journal of Psychoactive Drugs 2010, 42:227-238.
62. Ries R.K., Miller S.C., et al. Principles of addiction medicine 2009, Lippincott Williams & Wilkins.
63. Roski J., McClellan M. Measuring health care performance now, not tomorrow: Essential steps to support effective health reform. Health Affairs 2011, 30:682-689.
64. Shields M.C., Patel P.H., et al. A model for integrating independent physicians into accountable care organizations. Health Affairs 2011, 30:161-172.
65. Stein B.D., Gordon A.J., et al. The impact of buprenorphine on treatment of opioid dependence in a Medicaid population: Recent service utilization trends in the use of buprenorphine and methadone. Drug and Alcohol Dependence 2012, 123:72-78.
66. Thomas C.P., Garnick D.W., et al. Advancing performance measures for use of medications in substance abuse treatment. Journal of Substance Abuse Treatment 2011, 40:35-43.
67. Thomas C.P., Reif S., et al. Use of buprenorphine for addiction treatment: Perspectives of addiction specialists and general psychiatrists. Psychiatric Services (Washington, D.C.) 2008, 59:909-916.
68. Truven Health MarketScan Research Databases from. http://truvenhealth.com/your_healthcare_focus/pharmaceutical_and_medical_device/data_databases_and_online_tools.aspxhttp://thomsonreuters.com/products_services/healthcare/healthcare_products/pharmaceuticals/mktscan_res_db/.
69. Un H. Aetna Behavioral Health: Medication assisted treatment for alcohol use disorder: Presentation to the SAMHSA/Washington Circle expert panel on advancing performance measures for medication assisted treatment of substance use disorders 2009, Washington DC.
70. Un H. Medication assisted treatment for alcohol use disorder 2009, Presented at the SAMHSA/CSAT Invitational Conference on Economic Access to Treatment, Washington DC.
71. Waxmonsky J.G., Wilens T.E. Pharmacotherapy of adolescent substance use disorders: A review of the literature. Journal of Child and Adolescent Psychopharmacology 2005, 15:810-825.
72. Weisner C., Mertens J., et al. Integrating primary medical care with addiction treatment. JAMA: The Journal of the American Medical Association 2001, 286:1715.
73. Zarkin G.A., Bray J.W., et al. Cost and cost-effectiveness of the COMBINE study in alcohol-dependent patients. Archives of General Psychiatry 2008, 65:1214-1221.
74. Zerzan J.T., Morden N.E., et al. Trends and geographic variation of opiate medication use in state Medicaid fee-for-service programs, 1996 to 2002. Medical Care 2006, 44:1005-1010.